
EMA to Collaborate More Closely with Academia
EMA has developed a framework and action plan to foster relationships with the academic community.
On April 3, 2017, the European Medicines Agency (EMA) announced that it has developed a framework to further develop interactions with the academic community in the context of the European medicines regulatory network. The framework and three-year action plan were adopted by EMA’s management board during its March 2017 meeting, the agency said in a
“Academia play an important role in helping the EU medicines regulatory network keep abreast of the opportunities and challenges brought by science, be it in the context of the development, assessment or safety monitoring of medicines,” Guido Rasi, EMA’s executive director, said in a statement. “The framework will allow us to integrate cutting-edge scientific knowledge more tightly into our activities. It will also help academic start-ups benefit from advice from the EU regulatory network to translate their discoveries into patient-focused medicines.”
The frameworks overall objectives include:
- Raising awareness of the mandate and work of the European medicines regulatory network to increase academia’s trust in and engagement with the regulatory system
- fostering the translation of academic research into novel methodologies and medicines which meet regulatory standards and address needs of public and animal health
- ensuring that the best scientific expertise and academic research are available on time to support effective evidence generation, regulatory advice and guidance, as well as decision-making in regulatory processes
- working with academia to develop regulatory science that embraces scientific progress in medicines development without compromising patient safety, for example, the use of novel endpoints or novel methodologies.
The framework builds on EMA’s experience in interacting with stakeholder associations representing patients and consumers, healthcare professionals, and the pharmaceutical industry. Along with the framework, EMA has developed an
EMA also published today a new
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.